Delivery Order SPE2DB22D3009-SPE2DB25FBE29
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Boostrix TDAP vaccine in 0.5ml syringes. This competitively awarded, non-set-aside contract carries a ceiling value of $9,404.28 under a firm fixed-price arrangement, with performance to be completed by September 2, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical and healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Boostrix TDAP vaccine in 0.5 mL syringes. This competitively awarded, non-set-aside contract carries a ceiling value of $4,470.50 and is structured as a firm fixed price delivery order with an ultimate completion date of August 1, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains operations as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in syringe form (0.5mL) with a ceiling value of $1,064.40. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes no set-aside designation and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Boostrix TDAP vaccine in 0.5 mL syringes. This competitively awarded contract carries a firm fixed price ceiling value of $3,165.64 with an ultimate completion date of September 2, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,342.46 for Boostrix TDAP vaccine in 0.5mL syringe format on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a $13,446.66 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitive award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes, valued at $7,077.10 with a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 20, 2025, and represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5mL) on August 11, 2025, with a ceiling value of $22,083.83. This firm fixed-price contract, with an ultimate completion date of August 12, 2025, represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. The contract is unclassified as a set-aside and will be performed at the vendor's corporate office location in...
- The Defense Logistics Agency awarded a $4,733.48 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. This non-set-aside contract, which carries an ultimate completion date of August 14, 2025, operates under a firm fixed price structure. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this order. The contract represents a small-value transaction typical of routine...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $133,843.21 on August 12, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. The contract utilizes a firm fixed-price structure with no set-aside designation, indicating competitive award. Performance will be conducted at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order is executed under...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBE29Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Boostrix TDAP vaccine in 0.5ML syringes. This competitively awarded, non-set-aside contract carries a ceiling value of $1,865.25 with a firm fixed price structure and an ultimate completion date of September 2, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a transactional purchase under AmerisourceBergen's larger Indefinite Delivery Contract with the DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical prime vendor contract authorizes AmerisourceBergen to supply a broad range of pharmaceutical products, vaccines, and medical supplies to support military healthcare systems globally. As a major pharmaceutical distributor and established federal medical procurement partner, AmerisourceBergen regularly fulfills vaccine and specialty pharmaceutical requirements for Defense Health Agency and other government healthcare systems through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/29/25 |